Aurobac Therapeutics

Latest News

AUROBAC THERAPEUTICS welcomes two new Independent Members to its Board: Manos Perros, as Chairman, and Marco Taglietti

"We are thrilled to welcome Dr Manos Perros as our new Chairman of the Board and Dr Marco Taglietti as an Independent Member” said Frank Kalkbrenner, former Chairman of the Board, representing Boehringer Ingelheim, main shareholder of AUROBAC THERAPEUTICS. "As former CEOs of biotech companies which have successfully developed anti-infectives, their wealth of experience and strategic vision will be instrumental in guiding AUROBAC's future endeavors. We believe that their appointment will further strengthen our Board and enhance our ability to pursue our mission to develop and bring to market innovative products to fight AMR."

Know more

AUROBAC THERAPEUTICS announces appointment of Martin Everett as Chief Scientific Officer

Commenting on the appointment, AUROBAC THERAPEUTICS CEO Florence Séjourné: “I am delighted that Martin is joining us. His incredibly strong knowledge and experience will be instrumental in helping us achieve our ambitious goals and making a profound impact in the field of antimicrobial resistance.”

Know more

AUROBAC THERAPEUTICS appoints Florence Séjourné as Chief Executive Officer

“Florence’s is an experienced biotech leader with outstanding strategic and operational acumen. The Board has great confidence in her to successfully set-up and lead AUROBAC.” said Frank Kalkbrenner, Ph.D., Co-Founder and Chairman of the Board of AUROBAC.

Know more

Boehringer Ingelheim, Evotec and bioMérieux launch AUROBAC THERAPEUTICS, a joint venture to fight AntiMicrobial Resistance

The resulting company, AUROBAC THERAPEUTICS SAS, will combine the best-of-best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure.

Know more

AUROBAC THERAPEUTICS is proud to be a member of the BEAM Alliance

This website is a temporary version; a complete new website will be soon available!

Legal Notice